While in Israel, volunteer caregivers at a Tel Aviv hospital began receiving their 4th dose in a clinical trial before it could be generalized to all medical staff and those over 60, France could she, too, take the plunge? “The question is on the table”, affirmed Wednesday, December 29 on RTL Alain Fischer, professor of pediatric immunology and president of the Council of orientation of the vaccine strategy, while the 3rd dose is open to all adults since November 27.
“The subject is under consideration”, he said. But the decision depends on the results of studies on the effectiveness of the serum. “It is necessary to obtain the data concerning the level and the duration of protection conferred by the recall against the variant”, explained the specialist.
“Depending on the data, whether the protection against severe forms decreases or is stable at a very good level, depending on the age group, whether people are fragile or not”, “the need for an additional reminder” could be recommended, “either for all or for the fragile”.
This measure would occur “within a timeframe that I cannot specify today”, he warned. As for the vaccination strategy adopted by Israel, “maybe we will do the same thing, but we must allow time for scientific analysis of the data”, he explained. Before justifying: “The Israelis are out of step with us. They started their recall earlier than us and are between one and two months ahead of Europe in general.”